Uceris, Glumetza, and Zegerid — which this quarter had sales of $19.6M, $45.6M, and $27.1M, respectively — should help SLXP diversify its revenue stream. In Q3, Xifaxan accounted for nearly 70% of the top-line.
The companies say that post-merger, "no product is expected to account for more than 50% of the combined company's revenue."
Combined company Q3 results: Revenue of $1.348B and adjusted EBITDA of $537M.
SLXP expects "revenue synergies from the increased number of sales representatives in GI and the expanded presence in primary care."
FY14 combined company outlook: Adjusted EPS of $5. (PR)